Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables: 2020-2025

  • Kymera Therapeutics' Receivables was N/A to $40.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $62.0 million, marking a year-over-year change of. This contributed to the annual value of $18.8 million for FY2023, which is N/A change from last year.
  • Kymera Therapeutics' Receivables amounted to $40.0 million in Q2 2025, which was up 112.77% from $18.8 million recorded in Q4 2023.
  • Kymera Therapeutics' 5-year Receivables high stood at $40.0 million for Q2 2025, and its period low was $1.8 million during Q1 2021.
  • Its 2-year average for Receivables is $29.4 million, with a median of $29.4 million in 2023.